Triple Giving November logo for OMF Australia

 TRIPLE YOUR IMPACT during Triple Giving November | All Donations to OMFAU are TRIPLED through 1 December

How common is ME/CFS — and how has that changed?

ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) now affects an estimated 275 million people worldwide—a dramatic increase driven by the COVID-19 pandemic and Long COVID. In Australia, over 945,000 people are living with ME/CFS, and in New Zealand, 185,000. This widespread, often disabling condition highlights the urgent need for greater awareness, research, and support.

Personalised Treatment Trials (TOTEM)

The study aims to deeply characterise patients before, during and after treatments are trialled through their GP. Producing large scale data in combination with treatment outcome will be used to produce a predictive algorithm to improve the connection of patients to appropriate treatment options sooner.

Tracking Hormone Fluctuations in ME/CFS (MELLOW)

The study aims to investigate how hormone fluctuations in individuals with ME/CFS and Long COVID, compared to healthy controls, impact metabolism and immune pathways by measuring hormones, metabolites, and inflammation markers in biofluid samples.

Vascular Study of Orthostatic Intolerance in ME/CFS

Large blood cells coursing through a vein

The study aims to investigate the effects of supine vs upright exercise on cerebral blood flow, blood pressure, heart rate, and the presence of autoimmune antibodies in ME/CFS patients with orthostatic intolerance, compared to controls, to understand the underlying mechanisms and differences in symptom severity and post-exertional malaise.

25-Day Metabolite Monitoring Study of ME/CFS Patients

The study aims to meticulously analyse daily changes in metabolites from blood samples of individuals with ME/CFS over 25 days, to uncover the complex biological processes contributing to the condition and facilitate patient clustering by dynamic changes, thereby addressing the challenge of clinical and biological diversity within the ME/CFS population.

Crash-Course: Studying PEM in ME/CFS, PTLDS, Long COVID

The study aims to compare biological markers during mild symptoms and flare/PEM events in individuals with ME/CFS, alongside PTLDS and Long COVID patients, using finger-prick blood samples and continuous data from wearable sensors to understand symptom variability.

AusME Biobank Biomarker Project

Two scientists, one female, one male, working in a lab. The make is looking into a microscope and the female is using a pipet.

The study aims to utilise the Australian ME/CFS biobank for metabolomics analyses and other assays to identify potential biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, contributing to a comprehensive dataset for large-scale analysis.